{
    "nctId": "NCT05634954",
    "briefTitle": "Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer",
    "officialTitle": "A Phase 1 Study to Assess the Safety, Radiation Dosimetry and Biodistribution, and Basic Pharmacokinetics of [18F]GEH121224 and Determine the Optimal Timing of Imaging in Patients With Locally Advanced or Metastatic Breast Cancer.",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "Specific absorbed dose to the target lesions, specific absorbed dose per organ, and total effective dose of [18F]GEH121224.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients aged \u226518 years\n* Willingness and ability to comply with study procedures and signed and dated informed consent\n* For women of child-bearing potential, negative urine pregnancy test at screening and o on the day of investigational medicinal product (IMP) administration (with the result known before IMP administration) and willingness to use contraception (barrier, abstinence, non-hormonal) for 3 weeks after injection of \\[18F\\]GEH121224\n* Life expectancy \\>3 months\n* Diagnosis of locally advanced or metastatic breast cancer\n* Target lesion diameter of \u226515 mm that has not been previously treated with radiotherapy\n* Histologically confirmed locally advanced/metastatic breast cancer with a biopsy within the past 12 months confirming HER2-positive status by either IHC or FISH from primary tumor\n* Previously received no more than 1 prior lines of systemic chemotherapy (including anti HER2 therapy) for metastatic breast cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2\n* Adequate organ function as defined by:\n\nHemoglobin \u226510 g/dL White blood cell count \u22653.0 \u00d7 109/L Platelet count \u226575 \u00d7 109/L Serum creatinine \u22641.4 mg/dL Aspartate aminotransferase and alanine aminotransferase \u22642\u00d7 upper limit of normal (ULN) Total bilirubin \u22642\u00d7 ULN or 3.0 mg/dL in patients with Gilbert's syndrome\n\n* At least one lesion is fluorodeoxyglucose (FDG)-avid\n\nExclusion Criteria:\n\n* Patient has a primary non-breast malignancy (small dermatological malignancies such as basal cell carcinoma \\<10 mm are allowed)\n* Pregnancy or breast-feeding or, for women of child-bearing potential, unwillingness to use an acceptable form of birth control\n* Chronically active hepatitis B or C\n* Current history of drug or alcohol abuse or any active liver disease\n* Administration of other IMP within 30 days of screening\n* Systemic therapy including anti-HER2 therapy within 2 weeks before enrollment\n* Ongoing toxicity \\> grade 2 from previous standard or investigational therapies, according to National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 5.0\n* History of cardiac disease (myocardial infarction, arrhythmias requiring therapy, symptomatic valvular disease, cardiomyopathy, or pericarditis)\n* Evidence of significant medical condition, ongoing severe disease, or laboratory finding that, in the opinion of the Investigator, makes it undesirable for the patient to participate in the study\n* Severe claustrophobia, inability to lie flat or fit into the scanner (e.g., body weight \u2265350 lbs \\[160 kg\\]), or any other inability to tolerate the PET scan\n* Known allergies to any product used in this study or any constituents of GEH121224 (18F) Injection",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}